Healthcare / Medical DevicesHKSE
$0.22
-0.01 (-2.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-138.1M · quality 79.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$308M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-21.6%
↓Gross Margin
47.1%
↓Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-38.8%
FCF CAGR
—
FCF margin
-424.9%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.2M · net income $-77.1M · FCF $-81.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.2M | $19.2M | $39.8M | $73.2M | $83.6M |
| Net Income | $-77.1M | $-77.1M | $-113.5M | $-115.8M | $-1.35B |
| EBITDA | $-58.3M | $-58.3M | $-91.8M | $-93.5M | $-1.33B |
| EPS | — | — | -0.10 | -0.10 | -1.50 |
| Gross Margin | 47.1% | 47.1% | 59.9% | 66.3% | 83.5% |
| Operating Margin | -389.7% | -389.7% | -251.0% | -181.3% | -173.5% |
| Net Margin | -402.0% | -402.0% | -285.0% | -158.2% | -1609.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.06 | 0.04 | 0.05 |
| Current Ratio | 1.13 | 1.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-81.5M | $-81.5M | $-138.1M | $-235.3M | $-141.0M |
| Returns | |||||
| ROE | -21.6% | -21.6% | -27.9% | -22.5% | -217.6% |
| Valuation | |||||
| P/B | 0.86 | 0.86 | 0.46 | 0.97 | 2.24 |
| Growth & Yield | |||||
| Revenue Growth | -51.8% | -51.8% | -45.6% | -12.4% | — |
| EPS Growth | — | — | 0.0% | 93.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+45.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.10 → n/d
Residual
+45.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.